Davamotecan pegadexamer

N/A

Report date: 2023/06/13 20:00:42

Base Information

Drug NameDavamotecan pegadexamer
Drug Alias NamePoly-CD-PEG-camptothecinPoly(CD DCys-PA-PEG)-Gly-CPTLINEAR CYCLODEXTRIN-CYSTEINE-PEG BASED POLYMER CONJUGATE OF CAMPTOTHECINIT-101HG-6 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitorsHypoxia-inducible factor 1 alpha inhibitors
TargetsHypoxia-inducible factor 1 alphaDNA topoisomerase I
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursProstatic Neoplasms, Castration-Resistant +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineTaiwan +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesCalando Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteEllipses Pharma
Inactive CompaniesNewlink Genetics CoCerulean Pharma IncThe University Of Chicago
Active IndicationsProstatic NeoplasmsSmall Cell Lung CarcinomaLung Neoplasms +[6] 
Inactive IndicationsEsophageal adenocarcinomaSolid tumoursProstatic Neoplasms, Castration-Resistant +[11] 

Other Information

ATC CodeN/A
Related LinksN/A